Redeye provides an initial take on Harm Reduction Group’s Q3 report, where sales and EBITDA declined y-o-y, but the latter aligned with our ...
Redeye comments on yesterday’s vote in Stortinget (the Norwegian parliament), where the future legislation of flavoured and nicotine e-cigar...
Redeye trims its valuation range after reviewing Harm Reduction Group’s Q2 2023 report.
Redeye states that Harm Reduction Group’s Q2 2023 report was weaker on top-line than expected.
Redeye comments on the news that Norse Impact has reached an agreement with DAGAB on the supply of disposable e-cigarettes.
Redeye revises its estimates after reviewing Norse Impact’s Q1 2023 report.
Redeye comments on Norse Impact's Q1'23 report, noting that sales and profitability fell below expectations, primarily due to a weaker topli...
Redeye comments on the news that Norse Impact has decided to cancel the process regarding a potential partnership relating to medical cannab...
Redeye revises its estimates after reviewing Norse Impact’s Q4 2022 report.
Redeye highlights that Norse Impact's Q4 report revealed strong sales and positive EBITDA, although slightly lower than our expectations.
Redeye states that Norse Impact has received funding from Symetricus, a major European vape products producer, and has signed a distribution...
Redeye initiates coverage of Norse Impact, a leading distributor in the Nordic e-commerce segment for vapes.
